Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Acute Myeloid Leukemia (AML) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FLT3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | FLT3 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View FLT3 Products |
| Antigen (Resistance Mutants) | FLT3 Kinase Domain Mutant Proteins (ITD, D835Y, F691L) For drug resistance screening. High Purity, Theoretical MW verified. |
View FLT3 Products |
| Gene Delivery | FLT3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Suitable for Flow Cytometry and Internalization Assays. |
View FLT3 Products |
| Benchmark Ab | Anti-FLT3 Recombinant Antibody (Positive Control) Sequence-defined benchmark for binding and neutralization assays. |
View FLT3 Products |
| Validator | FLT3 siRNA Set For knockdown verification and specificity controls. |
View FLT3 Products |
| Related Target A | KIT (CD117) Type III RTK paralog; critical selectivity counter-screen to assess myelosuppression risk. |
View KIT Products |
| Related Target B | CD123 (IL3RA) Synergistic AML stem cell target; combination therapy and bispecific rationale. |
View CD123 Products |
| Related Target C | CD33 Synergistic target for dual-targeting AML therapies. |
View CD33 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Type III RTK selectivity (Counter-screen vs KIT, PDGFRA, CSF1R) | Homolog panel proteins strictly verified by mass spec; Sequence Verified HEK293 expression. |
| Resistance mutation profiling (FLT3-ITD, TKD mutations) | Mutant Recombinant Kinase Domain proteins available with >95% purity. |
| Cross-species cyno/mouse evaluation for biologics | Human / Mouse / Cyno ortholog ECD-Fc proteins available with >95% purity. |
| Lack of reliable controls | Clinical Benchmark Antibodies (Biosimilars) included for precise assay calibration. |
| False positives in knockdown | Validated siRNA included for specificity checks. |
Live FLT3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FLT3 therapeutics is intensifying, with major players shifting focus from first-generation pan-kinase inhibitors to highly selective next-generation small molecules and biologics. As frontline FLT3 inhibitors (e.g., Midostaurin) and relapsed/refractory agents (e.g., Gilteritinib) have established clinical utility, the next wave of R&D is targeting resistance mutations (FLT3-ITD, TKD), combination regimens with BCL-2 or hypomethylating agents, and novel modalities including ADCs, T-cell engagers, and CAR-T cells. Combination therapies, particularly with BCL-2 inhibitors, are also becoming a clinical standard, demanding highly specific reagents for robust preclinical modeling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Type III RTK-selective) | Astellas, Novartis, Daiichi Sankyo | AML (Frontline & R/R) | Selectivity Assay (Need Mutant vs WT Proteins; Off-target KIT/PDGFRA panel) |
| ADC | Emerging Biotech / Pharma | AML, High-Risk MDS | Internalization Assay (Need high-purity ECD-Fc; Stable cell line via Lentivirus) |
| Bispecific (e.g., FLT3/CD3) | Amgen, Regeneron, Early-Stage Biotech | R/R AML | Heterodimer Validation (Need Cross-reactive Abs; Cyno cross-reactivity) |
| CAR-T / Cell Therapy | Various Biotechs | Relapsed/Refractory AML | Cell Line Construction (Need Lentivirus for Stable Expression) |